Valuation: Biora Therapeutics, Inc.

Capitalization 8L 7L 6L 6L 11.16L 7.41Cr 11.67L 73.77L 29.21L 3.57Cr 30.69L 30.06L 13Cr P/E ratio 2022
-0.66x
P/E ratio 2023 -0.17x
Enterprise value 3.34Cr 2.83Cr 2.59Cr 2.46Cr 4.56Cr 302.9Cr 4.77Cr 30Cr 12Cr 145.82Cr 13Cr 12Cr 524.92Cr EV / Sales 2022
422x
EV / Sales 2023 17,337x
Free-Float
98.28%
Yield 2022 *
-
Yield 2023 -
More valuation ratios * Estimated data
Dynamic Chart
1 month 0
Extreme 0
0
Current year 0
Extreme 0
0
1 year 0
Extreme 0
0.34
3 years 0
Extreme 0
67
5 years 0
Extreme 0
1,583.08
10 years 0
Extreme 0
3,980
More quotes
Manager TitleAgeSince
Chief Executive Officer 59 08/11/2021
Chief Executive Officer 58 01/09/2021
Chief Tech/Sci/R&D Officer - 01/05/2023
Director TitleAgeSince
Chairman 63 01/11/2021
Director/Board Member 59 01/02/2019
Director/Board Member 51 01/06/2014
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-99.00%0.00% - - 4
-0.66%-3.17%+9.09%+97.32% 5.03TCr
+0.74%+2.76%+68.18%+7.83% 4.21TCr
-0.77%-4.47%+87.44%+656.87% 3.2TCr
+1.02%-6.27%-9.34%-24.46% 2.68TCr
+1.49%+6.64%+75.41%-41.80% 2TCr
+0.23%-6.03%+43.62%-29.28% 1.91TCr
-0.95%+4.49%+131.22% - 1.26TCr
+0.79%+0.79%+57.55%+118.24% 1.19TCr
Average -10.80%-1.67%+57.90%+112.10% 2.39TCr
Weighted average by Cap. +0.15%-1.22%+49.15%+126.59%
See all sector performances

Financials

2022 2023
Net sales 3L 3L 2L 2L 4L 2.76Cr 4L 27.5L 10.89L 1.33Cr 11.44L 11.2L 4.79Cr 4T 3.39T 3.1T 2.94T 5.46T 4L 5.71T 36.06T 14.28T 2L 15T 14.69T 6L
Net income -3.82Cr -3.23Cr -2.96Cr -2.8Cr -5.21Cr -345.69Cr -5.44Cr -34Cr -14Cr -166.42Cr -14Cr -14Cr -599.07Cr -12Cr -11Cr -9.63Cr -9.12Cr -17Cr -1.12TCr -18Cr -111.9Cr -44Cr -541.32Cr -47Cr -46Cr -1.95TCr
Net Debt 9.93Cr 8.4Cr 7.7Cr 7.29Cr 14Cr 899.3Cr 14Cr 89Cr 35Cr 432.93Cr 37Cr 36Cr 1.56TCr 3.26Cr 2.76Cr 2.53Cr 2.4Cr 4.45Cr 295.49Cr 4.65Cr 29Cr 12Cr 142.25Cr 12Cr 12Cr 512.08Cr
More financial data * Estimated data
Logo Biora Therapeutics, Inc.
Biora Therapeutics, Inc. is a biotechnology company, which is focused on creating smart pills designed for targeted drug delivery to the gastrointestinal (GI) tract, and systemic, needle-free delivery of biotherapeutics. The Company’s pipeline includes two therapeutic delivery platforms: NaviCap and BioJet. The NaviCap, targeted oral delivery platform, which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site of disease in the gastrointestinal tract. The BioJet, systemic oral delivery platform, which is designed to replace injection for better management of chronic diseases through needle-free, oral delivery of large molecules. It has two demonstration drug-device combination programs for the BioJet platform, BT-200 (GLP-1 receptor agonist) and BT-002 (adalimumab variant). Its other two programs include BT-600 (NaviCap + tofacitinib) and BT-001 (NaviCap + variant of adalimumab) for the treatment of ulcerative colitis.
Employees
58
More about the company
Date Price Change Volume

Delayed Quote OTC Markets, February 04, 2026 at 01:08 am IST

More quotes

Quarterly revenue - Rate of surprise